Corrigendum to “Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPV”
Table 3
Baseline characteristics of women enrolled in the four studies presented in the meta-analysis.
Study [reference]
Age mean (SD)
HPV 16 positivity at enrolment (%)
HPV 18 positivity at enrolment (%)
Lifetime number of sexual partners (median)
Smoking status (%)
Chlamydia trachomatis (%)
Hormonal contraceptive use (%)
Cytological abnormality at entry (%)
DNA
Serology
DNA
Serology
V
C
V
C
V
C
V
C
V
C
V
C
V
C
V
C
V
C
V
C
GSK [11, 12, 28]
20 ± 3
21 ± 3
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
PATRICIA [13, 27]
20 ± 3
20 ± 3
6
5
17
17
2
2
12
12
0
4%
4%
30
30
6
5
59
61
10
9
1
74%
74%
2
14%
15%
≥3
8%
8%
FUTURE I [16, 26, 30]
20 ± 2
20 ± 2
9
8
12
12
3
3
3
3
2
2
26
26
4
5
58
57
11
12
FUTURE II [17, 26, 30]
20 ± 2
20 ± 2
9
9
11
11
4
4
4
4
2
2
NR
NR
4
4
59
60
12
11
V: vaccine group; C: control group; NR: not reported. Results are presented as percentage of women stratified by number of sexual partners.
